DK0980242T3 - Anvendelse af fumarsyrederivater til behandling af autoimmunsygdomme - Google Patents

Anvendelse af fumarsyrederivater til behandling af autoimmunsygdomme

Info

Publication number
DK0980242T3
DK0980242T3 DK98919202T DK98919202T DK0980242T3 DK 0980242 T3 DK0980242 T3 DK 0980242T3 DK 98919202 T DK98919202 T DK 98919202T DK 98919202 T DK98919202 T DK 98919202T DK 0980242 T3 DK0980242 T3 DK 0980242T3
Authority
DK
Denmark
Prior art keywords
fumaric acid
treatment
acid derivatives
autoimmune diseases
administration
Prior art date
Application number
DK98919202T
Other languages
Danish (da)
English (en)
Inventor
Rajendra K Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Application granted granted Critical
Publication of DK0980242T3 publication Critical patent/DK0980242T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/60—Maleic acid esters; Fumaric acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK98919202T 1997-05-20 1998-04-01 Anvendelse af fumarsyrederivater til behandling af autoimmunsygdomme DK0980242T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19721099A DE19721099C2 (de) 1997-05-20 1997-05-20 Verwendung von Fumarsäurederivaten
PCT/EP1998/001894 WO1998052549A2 (de) 1997-05-20 1998-04-01 Verwendung von fumarsäurederivaten

Publications (1)

Publication Number Publication Date
DK0980242T3 true DK0980242T3 (da) 2003-04-14

Family

ID=7829995

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98919202T DK0980242T3 (da) 1997-05-20 1998-04-01 Anvendelse af fumarsyrederivater til behandling af autoimmunsygdomme

Country Status (24)

Country Link
US (1) US6436992B1 (cs)
EP (1) EP0980242B1 (cs)
JP (1) JP3881038B2 (cs)
CN (1) CN1153569C (cs)
AT (1) ATE232093T1 (cs)
AU (1) AU730441B2 (cs)
BG (1) BG64613B1 (cs)
BR (1) BR9809655A (cs)
CA (1) CA2248955C (cs)
CZ (1) CZ299960B6 (cs)
DE (2) DE19721099C2 (cs)
DK (1) DK0980242T3 (cs)
EE (1) EE03999B1 (cs)
ES (1) ES2190588T3 (cs)
HU (1) HU227697B1 (cs)
IL (1) IL132819A (cs)
NO (1) NO326815B1 (cs)
NZ (1) NZ501755A (cs)
PL (1) PL190864B1 (cs)
RS (1) RS49654B (cs)
RU (1) RU2197963C2 (cs)
SK (1) SK285897B6 (cs)
TR (1) TR199902587T2 (cs)
WO (1) WO1998052549A2 (cs)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
HU230252B1 (hu) * 2001-01-12 2015-11-30 Biogen Idec International Gmbh Fumársav-amid származékok
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
ES2297461T3 (es) * 2003-09-09 2008-05-01 Fumapharm Ag Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
EP2801355B1 (en) 2004-10-08 2015-05-20 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2007148744A1 (ja) * 2006-06-21 2007-12-27 Santen Pharmaceutical Co., Ltd. フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
RS63489B1 (sr) 2007-02-08 2022-09-30 Biogen Ma Inc Kompozicije i upotrebe za tretiranje multiple skleroze
LT2139467T (lt) * 2007-02-08 2016-10-10 Biogen Ma Inc. Neuroapsauga, sergant demielinizuojančia liga
CN102123763B (zh) 2008-08-19 2014-10-08 什诺波特有限公司 富马酸氢甲酯的前体药物、其药物组合物、及其使用方法
PT2379063E (pt) 2009-01-09 2013-05-03 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
CN102427727A (zh) 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
RS54551B1 (sr) 2010-02-12 2016-06-30 Biogen Ma Inc. Neuroprotekcija kod demijelinizujućih bolesti
MX2013013781A (es) * 2011-05-26 2014-01-08 Biogen Idec Inc Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina.
RS56972B1 (sr) 2011-06-08 2018-05-31 Biogen Ma Inc Postupak za pripremu visoko-čistog i kristalnog dimetil fumarata
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
AU2013203445C1 (en) 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
WO2013119791A1 (en) 2012-02-07 2013-08-15 Xenoport, Inc. Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
JP2015526477A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
EP3566701A1 (en) 2012-12-21 2019-11-13 Biogen MA Inc. Deuterium substituted fumarate derivatives
SG10201707543PA (en) 2013-03-14 2017-11-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
CN104415026A (zh) * 2013-08-31 2015-03-18 成都渊源生物科技有限公司 氘代富马酸衍生物在治疗多发性硬化症中的应用
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
WO2015127450A1 (en) 2014-02-24 2015-08-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
DE102014010832A1 (de) 2014-07-24 2016-01-28 Peter Krause Verwendung von medikamentösen Ingredienzien zur Behandlung von Multiple Sklerose
AU2015328676B2 (en) * 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
WO2016074684A1 (en) 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
WO2016126540A1 (en) * 2015-02-02 2016-08-11 Enspire Group LLC Stabilized dialkyl fumarate compositions
SG10201907289VA (en) 2015-02-08 2019-09-27 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
WO2016160635A1 (en) 2015-03-27 2016-10-06 Sytheon Limited Compositions and methods for treating psoriasis
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
BR112018016300A2 (pt) * 2016-02-12 2018-12-26 Univ Zuerich fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso
CN107973714A (zh) * 2017-12-26 2018-05-01 荆门医药工业技术研究院 一种富马酸单乙酯盐类的制备方法
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
US20230172894A1 (en) 2020-05-06 2023-06-08 Imcyse Sa Combination treatment for fumarate-related diseases
WO2022132978A1 (en) * 2020-12-18 2022-06-23 Upsher-Smith Laboratories, Llc Modified release solid oral dosage form for once daily administration of monomethyl fumarate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
US4346118A (en) * 1980-05-02 1982-08-24 University Of Delaware Antimicrobial agents added to animal feeds
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
DE3531597A1 (de) * 1985-09-04 1987-03-05 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US4768439A (en) * 1987-10-23 1988-09-06 Singer Stewart M Flare composition and flare comprising said composition
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
JPH06345644A (ja) * 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
JP3131112B2 (ja) * 1994-02-17 2001-01-31 株式会社資生堂 シクロスポリン含有乳化組成物
JPH07278187A (ja) * 1994-04-07 1995-10-24 Nippon Shinyaku Co Ltd シクロスポリン類のリン酸エステル誘導体及び医薬組成物
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB2291422A (en) * 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5763190A (en) * 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CN1125141A (zh) * 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물

Also Published As

Publication number Publication date
TR199902587T2 (xx) 2000-08-21
CA2248955C (en) 2001-08-14
CZ299960B6 (cs) 2009-01-07
CZ108099A3 (cs) 1999-08-11
DE19721099C2 (de) 1999-12-02
WO1998052549B1 (de) 1999-05-14
IL132819A0 (en) 2001-03-19
NO991342L (no) 1999-11-16
PL335381A1 (en) 2000-04-25
ES2190588T3 (es) 2003-08-01
YU57599A (sh) 2001-12-26
CN1153569C (zh) 2004-06-16
NO991342D0 (no) 1999-03-19
BG64613B1 (bg) 2005-09-30
BR9809655A (pt) 2000-07-11
HU227697B1 (en) 2011-12-28
DE59807122D1 (de) 2003-03-13
JP3881038B2 (ja) 2007-02-14
US6436992B1 (en) 2002-08-20
AU730441B2 (en) 2001-03-08
RS49654B (sr) 2007-09-21
EP0980242A2 (de) 2000-02-23
WO1998052549A3 (de) 1999-04-08
BG103335A (en) 2000-04-28
JP2000513023A (ja) 2000-10-03
DE19721099A1 (de) 1998-11-26
ATE232093T1 (de) 2003-02-15
EE03999B1 (et) 2003-04-15
WO1998052549A2 (de) 1998-11-26
NZ501755A (en) 2001-07-27
PL190864B1 (pl) 2006-02-28
AU7213698A (en) 1998-12-11
EP0980242B1 (de) 2003-02-05
CA2248955A1 (en) 1997-05-20
RU2197963C2 (ru) 2003-02-10
SK41599A3 (en) 2000-12-11
NO326815B1 (no) 2009-02-23
IL132819A (en) 2004-12-15
CN1257426A (zh) 2000-06-21
SK285897B6 (sk) 2007-10-04
HUP0001684A3 (en) 2001-09-28
HK1027512A1 (en) 2001-01-19
HUP0001684A2 (hu) 2000-09-28
EE9900535A (et) 2000-06-15

Similar Documents

Publication Publication Date Title
DK0980242T3 (da) Anvendelse af fumarsyrederivater til behandling af autoimmunsygdomme
DK1107749T3 (da) Anvendelse af fumarsyrederivater i transplantationsmedicin
DK0413528T3 (da) Amphotere præparater og polymere former af alphahydroxysyrer og deres terapeutiske anvendelse
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
NO20002172L (no) FremgangsmÕte for behandling av hyperkolesterolemi med usubstituert polydiallylamin
DE69805846D1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
ATE219081T1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
DE69614174D1 (de) Verfahren zur Herstellung von optisch-aktiven Gamma-substituierte-Hydroxy-Buttersäure-Ester
NZ337211A (en) Method of treating inflammatory, HIV diseases by using peptidyl boronic acid ester and acid compounds as proteasome inhibitors
DE69422064D1 (de) Verfahren zur Herstellung von optischaktiven 4-Halo-3-hydroxybuttersäure-Estern
ES2114616T3 (es) Acidos dicarboxilicos alifaticos insaturados.
HUP9701540A1 (hu) A gasztrointesztinális keringést elősegítő gyógyászati készítmény
DE69614375D1 (de) Dermatologische zubereitung zur behandlung von aktinischen keratosen
DK0883619T3 (da) Morfin- og diamorfinsalte af anioniske ikke-narkotiske analgetika af substitueret carboxylsyretype
DK0994704T3 (da) Anvendelse af GABA-analoger såsom gabapentin i fremstillingen af et medikament til behandling af inflammatoriske sygdomme
DE60040784D1 (de) Verfahren zur behandlung von inkontinenz
IT1293305B1 (it) Sali di acidi difosfonici e loro impiego farmacologico nel trattamento dell'osteoporosi
DE59300921D1 (de) Verfahren zur Herstellung von beta-Hydroxycarbonsäureestern.
DK0537313T3 (da) Arylalkylestere af 4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre med terapeutisk aktivitet
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
NO923393L (no) Fremgangsmaate for inhibering av korrosjon i broenner som syrebehandle
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DK0657431T3 (da) 4-Phenyl-3-substituerede 1,4-dihydropyridinestere med cerebral virkning.